Abstract
Approximately 50% of all men will eventually develop lower urinary tract symptoms (LUTS), the clinical hallmark of benign prostatic hyperplasia (BPH), and will require some form of medical or surgical intervention during their lifetime [1,2]. Transurethral resection of the prostate (TURP), introduced more than 50 years ago, is still the standard treatment of BPH against which other treatments are compared [3]. However, many medical and minimally invasive treatments for LUTS and BPH have been developed and investigated in the past 10 years, effectively competing with TURP in the treatment of men with BPH. There are many reasons for the desire on the part of both patients and physicians to develop therapeutic alternatives to TURP. Aside from the obvious hesitation on the part of patients to undergo a surgical procedure in general, there are well known and described risks associated with a TURP, which are summarized in the Agency for Health Care Policy and Research guidelines for the diagnosis and treatment of BPH [4]. A careful analysis of long-term outcome data further revealed that even the presumably definite TURP procedure has a sizable re-treatment rate over time, for which various estimates are available. The best estimate reports a rate of approximately 10% over 5 years of follow-up (2% per year) compared with a significantly lower rate of 2% over 5 years following open enucleation of the prostate [4]. An additional incentive for the development of treatment alternatives is the aging of the population, with more and more older men seeking therapy who have more comorbidities and higher anesthetic risks, making them an ideal target for medical and less or minimally invasive therapies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arrighi HM, Metter EJ, Guess HA, Fozzard JL: Natural history of benign prostatic hyperplasia and risk of prostatectomy. Urology 1991, 38: 4–8.
Barry MJ: Epidemiology and natural history of benign prostatic hyperplasia. In The Urologic Clinics of North America. Edited by Lepor H, Walsh PC. Philadelphia: WB Saunders; 1990: 495–507.
Wasson JH, Reda DJ, Bruskewitz RC, et al.: A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia: The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995, 332:75–79.
McConnell JD, Barry MJ, Bruskewitz RC, et al.: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline, Number 8. Edited by McConnell JD, Barry MJ, Bruskewitz RC, et al. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services; 1994.
Harada T, Etori D, Kumazaki T, et al.: Microwave surgical treatment of disease of the prostate. Urology 1985, 26:572–576.
Astrahan MA, Sapozink MD, Cohen D, et al.: Microwave applicator for transurethral hyperthermia of benign prostatic hyperplasia. Intl Hyperthermia 1989, 5:283–296.
de la Rosette JJMCH, D’Ancona FCH, Debruyne FMJ: Current status of thermotherapy of the prostate. J Urol 1997, 157: 430–438.
Ramon J, Goldwasser B, Shenfield O, et al.: Needle ablation using radio frequency current as a treatment for benign prostatic hyperplasia: experimental results in ex vivo human prostate. Eur Urol 1993, 24: 406–410.
Schulman CC, Zlotta AR, Rasor JS, et al.: Transurethral needle ablation (TUNA): safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia. Eur Urol 1993, 24:415–423.
Rasor S, Zlotta AR, Edwards SD, Schulman CC: Transurethral needle ablation (TUNA): thermal gradient mapping and comparison of lesion size in a tissue model and in patients with benign prostatic hyperplasia. Eur Urol 1993, 24: 411–414.
Schulman CC, Zlotta AR: Transurethral needle ablation of the prostate (TUNA): pathological, radiological and clinical study of a new office procedure for treatment of benign prostatic hyperplasia using low-level radiofrequency energy. Sem Urol 1994, 12: 205–210.
Schulman CC, Zlotta AR: Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: early clinical experience. Urology 1995, 45: 28–33.
Servadio C, Leib C: Hyperthermia in the treatment of prostate cancer. Prostate 1984, 5: 205–211.
Bernier PA, Roehrborn CG: Thermal therapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol 1997, 7: 15–20.
Gibbons RP, Mebust W, Smith P, et al.: Interventional therapy. In 4th International Consultation on Benign Prostatic Hyperplasia (BPH). Edited by Denis L, Griffiths K, Khoury S, et al. Plymouth, UK: Plymbridge Distributors Ltd.; 1997: 515–572.
de Wildt MJ, Tubaro A, Höfner K, et al.: Responders and nonresponders to transurethral microwave thermotherapy: a multicenter retrospective analysis [see comments]. J Urol 1995, 154:1775–1778.
Bosch JLHR: Urodynamic effects of various treatment modalities for benign prostatic hyperplasia. J Urol 1997, 158: 2034–2044.
de Wildt MJ, Tubano A, Hofner K, et al.: Responders and nonresponders to transurethral microwave thermotherapy: a multicenter retrospective analysis [see comments]. J Urol 1995, 154: 1775–1778.
Djavan B, Shariat S, Schafer B, Marberger M: Tolerability of high energy transurethral microwave thermotherapy with topical urethral anesthesia: results of a prospective, randomized, single-blinded clinical trial. J Urol 1998, 160: 772–776.
Ramon J, Goldwasser B, Shenfeld O, et al.: Needle ablation using radio frequency current as a treatment for benign prostatic hyperplasia: experimental results in ex vivo human prostate. Eur Urol 1993, 24:406–410.
Issa MM: Transurethral needle ablation of the prostate: report of initial US clinical trial. J Urol 1996, 156: 413–419.
Issa MM, Myrick SE, Symbas NP: The TUNA procedure for BPH: basic procedure and clinical results. Infect Urol 1998, Sept/Oct:148–154.
Roehrborn CG, Burkhard FC, Bruskewitz RC, et al.: The effects of transurethral needle ablation and resection of the prostate on pressure flow urodynamic parameters: analysis of the United States randomized study. J Urol 1999, 162: 92–97.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Current Medicine, Inc.
About this chapter
Cite this chapter
Bruskewitz, R.C. (2003). Minimally Invasive Therapies for Benign Prostatic Hyperplasia: Transurethral Microwave Thermotherapy and Needle Ablation. In: Bruskewitz, R.C. (eds) Atlas of the Prostate. Current Medicine Group, London. https://doi.org/10.1007/978-1-4615-6505-5_4
Download citation
DOI: https://doi.org/10.1007/978-1-4615-6505-5_4
Publisher Name: Current Medicine Group, London
Print ISBN: 978-1-4615-6507-9
Online ISBN: 978-1-4615-6505-5
eBook Packages: Springer Book Archive